A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumours That Express Nectin-4
The purpose of this study is to evaluate the safety and pharmacokinetics ASG-22CE as well as
assess the immunogenicity and antitumour activity in subjects with metastatic urothelial
cancer and other malignant solid tumours.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society